Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 in EBV-associated Lymphomas
NCT05882305Phase 1Withdrawn
- Sponsor
- Kousai Bio
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in Epstein-Barr virus associated lymphoma, sponsored by Kousai Bio. Primary endpoints: Incidence of dose-limiting toxicity at 1 year, Incidence of Effective dose range at 1 year and 1 more. Planned start Jun 2023; status: withdrawn.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
Epstein-Barr virus associated lymphoma
Beyond the preview
Go deeper on NCT05882305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882305.